Article
Phase II and UGT1A1 genotype study of irinotecan dose escalation as salvage therapy for advanced gastric cancer.
British journal of cancer - 8 May 2012
Jo J-C, Lee J-L, Ryu M-H, Chang H M, Kim M, Lee H J, Kim H-S, Shin J-G, Kim T-W, Kang Y-K
Abstract excerpt
BACKGROUND: To assess the efficacy and safety of individualised dose optimisation of irinotecan monotherapy as salvage treatment for advanced gastric cancer (AGC). METHODS: A total of 43 patients were enrolled. Intravenous irinotecan (350 mg m(-2)) was administered every 3 weeks. The dose was increased (425 mg m(-2) and 500 mg m(-2)) or decreased (250 mg m(-2)) depending on patient tolerance. UGT1A1 genotypes...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.